What's next after pola fails? new study tracks lymphoma patients' next moves
NCT ID NCT07310186
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 20 times
Summary
This study follows 200 adults with diffuse large B-cell lymphoma whose cancer got worse after treatment with polatuzumab vedotin. Researchers will track what treatments doctors try next and how well they work. The goal is to gather real-world data to help guide better treatment decisions for these patients in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.